ClinicalTrials.gg
CompletedNCT00065325EFECTUpdated Feb 24, 2015

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

A Phase 3 interventional study of Fulvestrant and Exemestane in Locally Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 117 sites in 15 countries. Open to female participants aged 32 Years to 91 Years. Per ClinicalTrials.gov, last updated 2015-02-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
694
Allocation
Randomized
Ages
32 Years to 91 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
10th of 94
694 · median 71
Started
2003
with 1 other
Phase 3
21 of 95
3 open now
Registered
4th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 10th largest by enrollment of the 94 interventional ones that give a count, is one of 2 that started in 2003, is one of 21 in phase 3, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 32 Years to 91 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.

03

Conditions studied

  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Locally advanced breast cancer
  • metastatic breast cancer
  • Breast Cancer
  • Cancer of Breast
  • Cancer of the Breast
04

Who can participate

Ages eligible
32 Years to 91 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmation of Breast Cancer
  • Breast Cancer has continued to grow after having received treatment with an aromatase inhibitor
  • women defined as a women who has stopped having menstrual periods
  • Evidence of hormone sensitivity
  • Written to participate in the trial

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane)
  • Any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor
  • Treatment with an or non-approved drug within one month
  • An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
  • A history of allergies to any active or inactive ingredients of Faslodex or Exemestane (i.e. castor oil or Mannitol)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
694 participants (actual)

Study arms

  • Active comparator
    1

    Exemestane

    Drug: Exemestane

  • Experimental
    2

    Fulvestrant

    Drug: Fulvestrant

Interventions

  • intramuscular injection

    Also known as: Faslodex, ZD9238

  • oral capsule

    Also known as: AROMASIN™

06

What researchers measure

Primary outcomes

  1. Time to disease progression (TTP)

    Time frame: after 580 Progression events accrued

Secondary outcomes

  1. Objective response rate

    Time frame: after 580 Progression events accrued

  2. Overall survival

    Time frame: after 580 Progression events accrued

  3. Duration of response

    Time frame: after 580 Progression events accrued

  4. Clinical Benefit

    Time frame: after 580 Progression events accrued

  5. Quality of Life

    Time frame: after 580 Progression events accrued

  6. PK

    Time frame: each visit

  7. Safety and tolerability.

    Time frame: after 580 Progression events accrued

07

Study locations

117 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Arcadia, California, United States
  • Research Site
    Fountain Valley, California, United States
  • Research Site
    Laverne, California, United States
  • Research Site
    Long Beach, California, United States
  • Research Site
    Santa Rosa, California, United States
  • Research Site
    Torrington, Connecticut, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Boca Raton, Florida, United States
  • Research Site
    Gainesville, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    New Port Richey, Florida, United States
  • Research Site
    Pensacola, Florida, United States
  • Research Site
    Athens, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Harvey, Illinois, United States
  • Research Site
    Springfield, Illinois, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    Overland Park, Kansas, United States
  • Research Site
    Baton Rouge, Louisiana, United States
  • Research Site
    Metairie, Louisiana, United States
  • Research Site
    New Orleans, Louisiana, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Bangor, Maine, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Frederick, Maryland, United States
  • Research Site
    Kalamazoo, Michigan, United States
  • Research Site
    Royal Oak, Michigan, United States
  • Research Site
    St Joseph, Michigan, United States
  • Research Site
    Hooksett, New Hampshire, United States
  • Research Site
    Livingston, New Jersey, United States
  • Research Site
    Voorhees, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Durham, North Carolina, United States
  • Research Site
    Canton, Ohio, United States
  • Research Site
    Hershey, Pennsylvania, United States
  • Research Site
    Lancaster, Pennsylvania, United States
  • Research Site
    Langhorne, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Providence, Rhode Island, United States
  • Research Site
    Columbia, South Carolina, United States
  • Research Site
    Greenville, South Carolina, United States
  • Research Site
    Spartenburg, South Carolina, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Burlington, Vermont, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Ciudad de Buenos Aires, Buenos Aires, Argentina
  • Research Site
    Mar Del Plata, Buenos Aires, Argentina
  • Research Site
    Rosario, Santa Fe, Argentina
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Brussels, Belgium
  • Research Site
    Leuven, Belgium
  • Research Site
    Ottignies, Belgium
  • Research Site
    Wilrijk, Belgium
  • Research Site
    Goiania, GO, Brazil
  • Research Site
    Rio de Janeiro, RJ, Brazil
  • Research Site
    Porto Alegre, RS, Brazil
  • Research Site
    Sao Paulo, SP, Brazil
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Penticton, British Columbia, Canada
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    St. John's, Newfoundland and Labrador, Canada
  • Research Site
    Kingston, Ontario, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    Newmarket, Ontario, Canada
  • Research Site
    Oshawa, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Sault Ste. Marie, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Windsor, Ontario, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Alborg, Denmark
  • Research Site
    Herning, Denmark
  • Research Site
    Hillerod, Denmark
  • Research Site
    Kobenhavn O, Denmark
  • Research Site
    Roskilde, Denmark
  • Research Site
    Sonderborg, Denmark
  • Research Site
    Bordeaux Cedex, France
  • Research Site
    Lille Cedex, France
  • Research Site
    Montpellier Cedex 5, France
  • Research Site
    Vandoeuvre Les Nancy, France
  • Research Site
    Augsburg, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Regensburg, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Szeged, Hungary
  • Research Site
    Haifa, Israel
  • Research Site
    Tel-aviv, Israel
  • Research Site
    Obninsk, Kaluga Region, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    St-petersburg, Russian Federation

Showing the first 100 of 117 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Jun 2006 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2003
First posted
Jul 23, 2003
Start
Aug 2003
Primary completionActual
Jun 2006
CompletionActual
Sep 2014
Last update
Feb 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00065325
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 23, 2003
Start date
Aug 2003
Primary completion
Jun 2006
Completion
Sep 2014
Last update
Feb 24, 2015

Study contacts

AstraZeneca Faslodex Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion